Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction

被引：0
|
作者：
Hellenkamp, Kristian [1 ,2 ]
Sato, Ryosuke [1 ,2 ]
von Haehling, Stephan [1 ,2 ]
机构：
[1] Univ Gottingen, Med Ctr, Dept Cardiol & Pneumol, Robert-Koch-Str 40, D-37075 Gottingen, Germany
[2] German Ctr Cardiovasc Res DZHK, Partner Site Lower Saxony, Gottingen, Germany
来源：
MED | 2025年 / 6卷 / 02期
关键词：
D O I：
10.1016/j.medj.2024.12.004
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The SUMMIT trial(1) showed that the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide improves quality of life and reduces worsening heart failure (HF) events in patients with HF with preserved ejection fraction (HFpEF) and obesity. Some concerns, however, remain.
引用
收藏
页码：1 / 4
页数：4
相关论文
共 50 条
  • [41] Heart Failure With Preserved Ejection Fraction
    Rogers, Felix J.
    Gundala, Teja
    Ramos, Jahir E.
    Serajian, Asif
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2015, 115 (07): : 432 - 442
  • [42] Heart failure with preserved ejection fraction
    Marzia Rigolli
    Gillian A Whalley
    Journal of Geriatric Cardiology, 2013, (04) : 369 - 376
  • [43] Parathyroid hormone is associated with heart failure with preserved ejection fraction
    Bezgin, T.
    Elveran, A.
    Karagoz, A.
    Canga, Y.
    Dogan, C.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2016, 117 (08): : 442 - 447
  • [44] Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
    Graziani, Francesca
    Lillo, Rosa
    Crea, Filippo
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [45] Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
    Borlaug, Barry A.
    Zile, Michael R.
    Kramer, Christopher M.
    Baum, Seth J.
    Hurt, Karla
    Litwin, Sheldon E.
    Murakami, Masahiro
    Ou, Yang
    Upadhyay, Navneet
    Packer, Milton
    NATURE MEDICINE, 2025, 31 (02) : 544 - 551
  • [46] The Conundrum of Patient Selection in Trials of Heart Failure With Preserved Ejection Fraction: Exploring the Benefits and Risks of Focused Phenotyping
    Plehn, Jonathan F.
    JOURNAL OF CARDIAC FAILURE, 2017, 23 (07) : 525 - 527
  • [47] Statins Beneficial for Heart Failure With Preserved Ejection Fraction But Not Heart Failure With Reduced Ejection Fraction?
    Ohte, Nobuyuki
    Little, William C.
    CIRCULATION JOURNAL, 2015, 79 (03) : 508 - 509
  • [48] Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction
    Montero-Perez-Barquero, Manuel
    Escobar-Cervantes, Carlos
    Llacer, Pau
    Quiros-Lopez, Raul
    Trullas, Joan C.
    Cerqueiro, Jose M.
    Epelde-Gonzalo, Francisco
    Carrera-Izquierdo, Margarita
    Formiga, Francesc
    Gonzalez-Franco, Alvaro
    Casado-Cerrada, Jesus
    FUTURE CARDIOLOGY, 2023, 19 (06) : 333 - 342
  • [49] Heart failure with preserved ejection fraction: Is this diastolic heart failure?
    Zile, MR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) : 1519 - 1522
  • [50] Is heart failure with midrange ejection fraction similar to preserved ejection fraction? For
    Babkowski, M. Camafort
    REVISTA CLINICA ESPANOLA, 2017, 217 (05): : 296 - 298
12345